Research ExplorerPublicationsSystemic therapy in recurrent ovarian cancer: current treatm...

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

Standard

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. / Harter, Philipp; Hilpert, Felix; Mahner, Sven; Heitz, Florian; Pfisterer, Jacobus; Andreas, Du Bois.

In: EXPERT REV ANTICANC, Vol. 10, No. 1, 1, 01.01.2010, p. 81-88.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Harter, P, Hilpert, F, Mahner, S, Heitz, F, Pfisterer, J & Andreas, DB 2010, 'Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.', EXPERT REV ANTICANC, vol. 10, no. 1, 1, pp. 81-88. https://doi.org/10.1586/era.09.165

APA

Harter, P., Hilpert, F., Mahner, S., Heitz, F., Pfisterer, J., & Andreas, D. B. (2010). Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. EXPERT REV ANTICANC, 10(1), 81-88. [1]. https://doi.org/10.1586/era.09.165

Vancouver

Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, Andreas DB. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. EXPERT REV ANTICANC. 2010 Jan 1;10(1):81-88. 1. https://doi.org/10.1586/era.09.165

Bibtex

@article{78c166d577824f1d94a85dcb84399f15,
title = "Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.",
abstract = "Most patients with ovarian cancer relapse despite aggressive surgery and platinum-taxane-based primary chemotherapy. Further treatment depends on prior response and progression-free interval. Monotherapy is indicated in patients with so-called platinum-resistant or -refractory ovarian cancer. The standard treatment for patients with platinum-sensitive recurrent ovarian cancer is platinum-based combination chemotherapy. Cytoreductive surgery is also a treatment option in such patients. Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer.",
keywords = "Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Time Factors, Treatment Outcome",
author = "Philipp Harter and Felix Hilpert and Sven Mahner and Florian Heitz and Jacobus Pfisterer and Andreas, {Du Bois}",
year = "2010",
month = jan,
day = "1",
doi = "10.1586/era.09.165",
language = "English",
volume = "10",
pages = "81--88",
journal = "EXPERT REV ANTICANC",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

AU - Harter, Philipp

AU - Hilpert, Felix

AU - Mahner, Sven

AU - Heitz, Florian

AU - Pfisterer, Jacobus

AU - Andreas, Du Bois

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Most patients with ovarian cancer relapse despite aggressive surgery and platinum-taxane-based primary chemotherapy. Further treatment depends on prior response and progression-free interval. Monotherapy is indicated in patients with so-called platinum-resistant or -refractory ovarian cancer. The standard treatment for patients with platinum-sensitive recurrent ovarian cancer is platinum-based combination chemotherapy. Cytoreductive surgery is also a treatment option in such patients. Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer.

AB - Most patients with ovarian cancer relapse despite aggressive surgery and platinum-taxane-based primary chemotherapy. Further treatment depends on prior response and progression-free interval. Monotherapy is indicated in patients with so-called platinum-resistant or -refractory ovarian cancer. The standard treatment for patients with platinum-sensitive recurrent ovarian cancer is platinum-based combination chemotherapy. Cytoreductive surgery is also a treatment option in such patients. Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Disease-Free Survival

KW - Drug Resistance, Neoplasm

KW - Female

KW - Humans

KW - Neoplasm Recurrence, Local

KW - Ovarian Neoplasms

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1586/era.09.165

DO - 10.1586/era.09.165

M3 - SCORING: Journal article

C2 - 20014888

VL - 10

SP - 81

EP - 88

JO - EXPERT REV ANTICANC

JF - EXPERT REV ANTICANC

SN - 1473-7140

IS - 1

M1 - 1

ER -